Video

Dr. Kaufman hails autologous muscle-derived cells as "transformational" SUI treatment

Author(s):

Urology Times staff

“This technology is truly a transformational opportunity for urology,” says Melissa R. Kaufman, MD, PhD, FACS.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Melissa R. Kaufman, MD, PhD, FACS, discusses autologous muscle derived cells for urinary sphincter repair (AMDC-USR) and how this technology is designed to treat stress urinary incontinence (SUI) in female patients. Kaufman is a professor of urology and chief of the division of reconstructive urology and pelvic health at Vanderbilt University, Nashville, Tennessee.

      Related Videos
      Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
      Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
      Karyn S. Eilber, MD, answers a question during a Zoom video interview
      Karyn S. Eilber, MD, on patient counseling for onabotA treatment for OAB
      Woman at doctor | Image Credit: © rocketclips - stock.adobe.com
      Optimizing onabotA for OAB: What are some common misconceptions?
      Ruchika Talwar, MD, on how urologists can get involved in advocacy
      Ruchika Talwar, MD, on how urologists can get involved in advocacy
      Closeup of patient with prescription | Image Credit: © gpointstudio - stock.adobe.com
      Investigators characterize vibegron prescribing patterns for OAB
      Ruchika Talwar, MD, discusses ongoing drug shortages in urology
      Ruchika Talwar, MD, discusses ongoing drug shortages in urology
      Colin Goudelocke, MD, answers a question during a Zoom video interview
      Expert outlines advantages of batteryless sacral neuromodulation device
      Emmanuel Chartier-Kastler, MD, shares initial data on UroActive System in women with SUI
      Emmanuel Chartier-Kastler, MD, shares initial data on UroActive System in women with SUI
      Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
      Smaller size, patient control advantages of neurostimulator for OAB
      Batteryless neurostimulator found efficacious at 6-month follow-up
      Batteryless neurostimulator found efficacious at 6-month follow-up
      Related Content
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      May 1st 2025

      Safety, efficacy of vibegron sustained in men with OAB treated for BPH

      Benjamin P. Saylor
      The investigators reported an overall incidence of AEs of 29.6%.
      Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause
      April 28th 2025

      Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

      Melissa Kaufman, MD, PhD, FACS
      In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.
      Neuromodulation device shows promising efficacy for neurogenic bladder
      April 16th 2025

      Neuromodulation device shows promising efficacy for neurogenic bladder

      Hannah Clarke
      Data from the pivotal CONTINENCE trial showed encouraging efficacy of SCONE neuromodulation therapy.
      Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
      March 21st 2022

      Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

      Urology Times staff
      “This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
      Faceless view of senior man talking to doctor in bright light while taking notes on clipboard | Image Credit: © DragonImages - stock.adobe.com
      April 3rd 2025

      Kiran Sury, MD, on implementing ProACT for incontinence

      Kiran Sury, MD
      "In terms of making it a safe, highly reliable operation, if you're comfortable with slings and sphincters, you are very well positioned to learn this surger," says Kiran Sury, MD.
      FDA grants 510(k) clearance to Glean Urodynamics System
      April 2nd 2025

      FDA grants 510(k) clearance to Glean Urodynamics System

      Hannah Clarke
      "Glean will enable patients to void naturally, without catheters in place. I believe this advance will yield a better test that mimics actual symptoms," says Bilal I. Chughtai, MD.
      © 2025 MJH Life Sciences

      All rights reserved.